-
1 Comment
Shandong Sinobioway Biomedicine Co., Ltd is currently in a long term uptrend where the price is trading 4.3% above its 200 day moving average.
From a valuation standpoint, the stock is 318.5% more expensive than other stocks from the Basic Materials sector with a price to sales ratio of 16.8.
Shandong Sinobioway Biomedicine Co., Ltd's total revenue sank by 59.2% to $55M since the same quarter in the previous year.
Its net income has dropped by 157.6% to $-14M since the same quarter in the previous year.
Finally, its free cash flow grew by 413.6% to $26M since the same quarter in the previous year.
Based on the above factors, Shandong Sinobioway Biomedicine Co., Ltd gets an overall score of 2/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE1000012Y5 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | 5B |
|---|---|
| Beta | 0.37 |
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | None |
Shandong Sinobioway Biomedicine Co., Ltd. engages in the pharmaceutical manufacturing industry in China. The company is involved in the chemical raw materials, chemical product manufacturing, and biopharmaceutical manufacturing; production and sales of medicines. It also offers operating chemical products, such as trimethyl ester and triethyl ester. The company was founded in 2000 and is based in Shenzhen, China. Shandong Sinobioway Biomedicine Co., Ltd. is the subsidiary of Shenzhen Yilian Technology Co., Ltd.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002581.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026
